New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 13, 2014
07:33 EDTNBSNeoStem announces licensing agreement, plans to begin Phase 2 HCC trial in China
NeoStem announced that the company has signed an exclusive license agreement with China-based Cellular Biomedicine Group to begin a Phase 2 clinical trial in patients with late stage liver cancer. The trial, to be conducted in China in accordance with international standards, will investigate the use of the Company's developmental patient-specific cancer immunotherapy known as "DC-TC", in patients with hepatocellular carcinoma, or HCC. Pursuant to the terms of the license agreement, the cost of the Phase 2 trial will be borne by CBMG, and CBMG will also be responsible for all clinical, marketing, and, should a product be approved, commercialization activities in China. NeoStem will be responsible for all regulatory filings and will directly control and manage all manufacturing processes and procedures relating to the development of its DC-TC product. NeoStem could receive up to $30M in licensing milestone fees over the life of the agreement, with $1M payable upon enrollment of the first patient in the currently planned Phase 2 trial. Royalties and sublicense fees may also be payable. The company's DC-TC therapy involves growing cancer initiating cells that have been isolated from a patient's resected tumor sample, and then enriching and inactivating them. This newly created cancer initiating cell line is then combined with dendritic cells, a type of antigen-presenting immune cell that is derived from the same patient's blood. The product is then reintroduced to the patient via a series of subcutaneous injections. The planned study follows a Phase 1 trial which demonstrated safety in HCC patients. There were no serious adverse events related to the treatment in patients who co-presented with active hepatitis B and underlying cirrhosis, commonly associated with liver cancer in China, and patients were not charged for treatment.
News For NBS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
May 29, 2015
08:31 EDTNBSNeoStem plans to change name to Caladrius Biosciences
Subscribe for More Information
May 28, 2015
09:27 EDTNBSOn The Fly: Pre-market Movers
HIGHER: Rally Software (RALY), up 44% after deal to be bought by CA Technologies for $19.50 per share... IMAX (IMAX), up 6.5% after IMAX China files application for IPO on Hong Kong Stock Exchange... Avago (AVGO), up 2.8% after announcing deal to buy Broadcom (BRCM) for $37B in cash and stock. Broadcom shares are down 1% following the announcement... Western Digital (WDC), up 2.4% following upgrade to Buy from Neutral at Goldman. UP AFTER EARNINGS: Express (EXPR), up 8%... Abercrombie & Fitch (ANF), up 4.3%. LOWER: NeoStem (NBS), down 22.8% after 12.5M share secondary price at $2 per share... (CTRP), down 1.6% after reportedly disclosing cyberattack against its services. DOWN AFTER EARNINGS: Orbital ATK (OA), down 1.6%... Signet (SIG), down 3.5%... Sanderson Farms (SAFM), down 3%... Dangdang (DANG), down 11%.
May 27, 2015
19:14 EDTNBSOn The Fly: After Hours Movers
Subscribe for More Information
18:55 EDTNBSNeoStem 12.5M share Secondary priced at $2.00
Aegis acted as sole book running manager for the offering.
16:02 EDTNBSNeoStem files to sell common stock, no amount given
Aegis Capital Corp. is acting as sole book-running manager for the offering
May 26, 2015
07:33 EDTNBSNeoStem appoints Merrick Ross as lead for NeoStem's Intus study
Subscribe for More Information
May 21, 2015
15:19 EDTNBSNeoStem spikes higher, levels to watch
The shares are spiking sharply, last up more than 45% to $3.30. At that price next resistance is at the session high at $3.47 and then at $3.71. Support is at $3.17.
15:17 EDTNBSNeoStem up over 40% after getting $17.7M grant for metastatic melanoma treatment
Subscribe for More Information
15:15 EDTNBSNeoStem gets $17.7M grant for metastatic melanoma treatment
Subscribe for More Information
15:11 EDTNBSNeoStem gets $17.7M grant from CIRM

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use